Janssen/J&J Invokana wins US SGLT2 race; 5 postmarket studies required
This article was originally published in Scrip
With the FDA's nod on 29 March for Invokana (canagliflozin), Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, triumphed in the race to have the first selective sodium glucose co-transporter 2 (SGLT2) inhibitor approved for the US market to treat adults with Type II diabetes – beating other competitors Boehringer Ingelheim's and Lilly's empagliflozin and AstraZeneca's and Bristol-Myers Squibb's dapagliflozin.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.